We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/2/2022 19:53 | We need it don't we! | jpuff | |
04/2/2022 15:42 | Let's hope this gets moving again | michelle74 | |
04/2/2022 12:27 | Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn's DiseaseFebruary 4, 2022 at 7:00 AM EST | jpuff | |
03/2/2022 20:19 | It'll start rising once all the loons have got fed up and left | jpuff | |
03/2/2022 16:23 | hxxps://ir.tizianali IND for TZLS 501 submitted. Lots of news to come. | stenick | |
02/2/2022 21:15 | Along with the usual risk warning associated with growth companies | jpuff | |
02/2/2022 21:07 | Prospectus issued.... "We may offer, issue and sell from time to time up to $250,000,000, or its equivalent in any other currency, currency units, or composite currency or currencies, of our common shares, warrants to purchase common shares, and a combination of such securities, separately or as units, in one or more offerings. This prospectus provides a general description of offerings of these securities that we may undertake. | jpuff | |
01/2/2022 17:49 | Well lean the predessors didn’t get as far as these have. The only connection I can see is Willy simom the rest are history.No offence meant Willy. | stenick | |
31/1/2022 20:52 | Their predecessors have a history of not accomodating shareholder value, whilst not taking anything to market. The only thing they did correctly was 'coining it' with the millions funded courtesy of the naive 'herd'. | lean5gb | |
31/1/2022 10:58 | "It’s about patience guys" No, it is about patients and with regards to Accustem this dreadful Company has done them a dis-service but failing to bring this superior prognostic test to market. | nerdofsteel | |
30/1/2022 14:43 | It's about patience guys. As the Sage of Omaha quoted, the market takes from the inpatient and rewards the patient. I'm patient, along with Sten, so all is fine. I'm sure the others won't be on this board while I'm still around lol | jpuff | |
28/1/2022 18:14 | On you head be it fang, don’t say you weren’t warned. | stenick | |
28/1/2022 17:55 | FAO BOD - Fool me once, shame on you; fool me twice, shame on me - We wont be fooled again, now pack up your trickster show and GTF.... | fandagle | |
28/1/2022 16:37 | Oh you lucky people, we are now at the beginning. | stenick | |
27/1/2022 17:18 | Well yes Frank, thats investing for ya! | stenick | |
27/1/2022 14:57 | Probably using the $5 million this year to help prop price above $1 to prevent delisting. | ynot5 | |
27/1/2022 13:47 | Is that with PIs money then Sten! | one_frankel | |
26/1/2022 17:30 | He will probably get a $100mill for the $5mill shares he buys simples LOL. | stenick | |
26/1/2022 16:13 | The Company is quite rightly burning cash and probably needs in excess of $100m to get the two drug candidates through the next clinical trials. Why in that position would they do a buyback? AT&T, Microsoft and Pfizer do share buybacks, not these people. Something is very very wrong here (still). | nerdofsteel | |
24/1/2022 17:28 | They raised around $57 million for their programs at $5.20, yet they have the audacity to state a menial stock repurchase program of upto $5 million when not only do they require funding to realise those trials but the faithful are seriously underwater here...Bravo GC, played like a true shark! | one_frankel |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions